Completion of guideline-recommended initial evaluation of atrial fibrillation

Clinical Cardiology

Volumn 35, Issue 10, 2012, Pages 585-593

  Sinner, Moritz F ^a,b,c   Greiner, Melissa A ^d   Mi, Xiaojuan ^d   Hernandez, Adrian F ^d,e   Jensen, Paul N ^f,g   Piccini, Jonathan P ^d,e   Setoguchi, Soko ^d,e   Walkey, Allan J ^h   Heckbert, Susan R ^f,g   Benjamin, Emelia J ^a,i,j   Curtis, Lesley H ^d,e  

^a FRAMINGHAM HEART STUDY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f University of Washington School of Public Health   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h Pulmonary Center   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COMORBIDITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRACTICE GUIDELINE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEX FACTORS; STATISTICS, NONPARAMETRIC; THYROID FUNCTION TESTS; YOUNG ADULT;

EID: 84867232966     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22055     Document Type: Article

References (40)

1. McManus DD, Xanthakis V, Sullivan LM, et al. Longitudinal tracking of left atrial diameter over the adult life course: clinical correlates in the community. Circulation. 2010; 121: 667-674.
2. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995; 98: 476-484.
3. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 110: 1042-1046.
4. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271: 840-844.
5. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001; 38: 1231-1266.
6. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: e257-e354.
7. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369-2429.
8. Hansen LG, Chang S., Health research data for the real world: the MarketScan databases. http://info.thomsonhealthcare.com/- forms/ HealthResearchWPRequest. Accessed October 28, 2011.
9. Ghate SR, Biskupiak J, Ye X, et al. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm. 2011; 17: 672-684.
10. Ladapo JA, David G, Gunnarsson CL, et al. Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation. J Cardiovasc Electrophysiol. 2012; 23: 1-8.
11. Rural-urban commuting area codes. http://www.ers.usda.gov/-data/ ruralurbancommutingareacodes. Accessed November- 30, 2010.
12. RUCA data. http://depts.washington.edu/uwruca/ruca-uses.php. Accessed November 30, 2010.
13. Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005; 43: 480-485.
14. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43: 1130-1139.
15. Brenner H, Arndt V, Gefeller O, et al. An alternative approach to age adjustment of cancer survival rates. Eur J Cancer. 2004; 40: 2317-2322.
16. Sehgal A, Davies EA., Comparing treatment trends for colorectal cancer in clinical database and cancer registry data: implications for monitoring cancer care. J Eval Clin Pract. 2011; 17: 486-492.
17. Chou AF, Scholle SH, Weisman CS, et al. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues. 2007; 17: 120-130.
18. Piccini JP, Hernandez A, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009; 54: 1280-1289.
19. Barocas D, Penson D., Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int. 2010; 106: 322-328.
20. Krupski TL, Kwan L, Afifi AA, et al. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol. 2005; 23: 7881-7888.
21. Lentine KL, Schnitzler MA, Xiao H, et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med. 2010; 363: 724-732.
22. Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999; 22: 403-408.
23. Chan L, Giardino N, Rubenfeld G, et al. Geographic differences in use of home oxygen for obstructive lung disease: a national Medicare study. J Rural Health. 2010; 26: 139-145.
24. Goodney PP, Travis LL, Malenka D, et al. Regional variation in carotid artery stenting and endarterectomy in the Medicare population. Circ Cardiovasc Qual Outcomes. 2010; 3: 15-24.
25. Guadagnoli E, Landrum MB, Normand SL, et al. Impact of underuse, overuse, and discretionary use on geographic variation in the use of coronary angiography after acute myocardial infarction. Med Care. 2001; 39: 446-458.
26. Kumar A, Fonarow G, Eagle K, et al. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009; 8: 104-111.
27. Buccelletti F, Carroccia A, Marsiliani D, et al. Utility of routine thyroid-stimulating hormone determination in new-onset atrial fibrillation in the ED. Am J Emerg Med. 2011; 29: 1158-1162.
28. Krahn AD, Klein GJ, Kerr CR, et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med. 1996; 156: 2221-2224.
29. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994; 331: 1249-1252.
30. Heeringa J, Hoogendoorn EH, van der Deure WM, et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med. 2008; 168: 2219-2224.
31. Danese MD, Powe NR, Sawin CT, et al. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA. 1996; 276: 285-292.
32. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999; 282: 1458-1465.
33. Ellrodt AG, Conner L, Riedinger M, et al. Measuring and improving physician compliance with clinical practice guidelines. A controlled interventional trial. Ann Intern Med. 1995; 122: 277-282.
34. Francke A, Smit M, de Veer AJ, et al. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak. 2008; 8: 38.
35. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009; 301: 831-841.
36. Makar GA, Weiner MG, Kimmel SE, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2008; 17: 43-51.
37. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011; 57: 173-180.
38. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
39. Riley GF., Administrative and claims records as sources of health care cost data. Med Care. 2009; 47: S51-S55.
40. Hansen K., Medicare and the laboratory. Clin Lab Sci. 2009; 22: 94-98.